#Phase1Trial
LightNews LightNews
gmj-georgia.bsky.social
🔬 New phase 1 trial in Nature Medicine: Bispecific antibody 10E8.4/iMab safely targets HIV through dual mechanisms in both HIV+ an…

#Broadlyneutralizingantibody #HIV #Monoclonalantibody #Phase1trial #Therapeuticdevelopment

#Broadlyneutralizingantibody #HIV #Monoclonalantibody #Phase1trial #Ther…
Bispecific HIV Antibody Passes First Human Trial
🔬 New phase 1 trial in Nature Medicine: Bispecific antibody 10E8.4/iMab safely targets HIV through dual mechanisms in both HIV+ an… #Broadlyneutralizingantibody #HIV #Monoclonalantibody #Phase1trial #Therapeuticdevelopment
news.gmj.ge
September 24, 2026 at 5:26 AM
gmj-georgia.bsky.social
Nature Medicine has published an author correction for the ABBV-706 phase 1 trial, a SEZ6-targeting antibody-drug conjugate being tested in a…

#ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Smallcelllungcancer

#ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Sm…
ABBV-706 Phase 1 Trial Correction Published
Nature Medicine has published an author correction for the ABBV-706 phase 1 trial, a SEZ6-targeting antibody-drug conjugate being tested in a… #ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Smallcelllungcancer
news.gmj.ge
September 14, 2026 at 7:26 AM
gmj-georgia.bsky.social
Nature Medicine has published an author correction for the ABBV-706 phase 1 trial, a SEZ6-targeting antibody-drug conjugate being tested in a…

#ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Smallcelllungcancer

#ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Sm…
ABBV-706 Phase 1 Trial Correction Published
Nature Medicine has published an author correction for the ABBV-706 phase 1 trial, a SEZ6-targeting antibody-drug conjugate being tested in a… #ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Smallcelllungcancer
news.gmj.ge
September 3, 2026 at 10:41 AM
bionewscentral.com
#Phase1Trial reports positive results for a #brain -protective #immunotherapy in early #AlzheimersDisease.
Immune therapy for Alzheimer's disease takes a step forward – BioNews Central
Phase 1 trial reports positive results for a brain-protective immunotherapy in early Alzheimer's disease. ...
sbee.link
August 4, 2026 at 4:49 PM
hemehub.bsky.social
🩺💡Today’s clinical questions!

Swipe to see the answers and explanations!

#Engasertib #AKTInhibitor #AKTPathway #BreastCancer #Oncology #CancerResearch #ClinicalTrials #Phase1Trial #NEJM #MedicalEducation #OncologyEducation #MedEd #CancerCare #AdverseEvents #OncTwitter #HemeOnc #HEMEHUB
June 25, 2026 at 2:00 AM
gl-hooper.bsky.social
🚨New data on inhaled siRNA therapies for respiratory viruses!
ascpt.onlinelibrary.wiley.com/doi/10.1111/...
#COVID19 #SARSCoV2 #Antivirals #ClinicalTrials #RNAtherapy #Phase1Trial
Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide‐Spectrum SARS‐CoV‐2, in Healthy Subjects
Severe acute respiratory syndrome caused by the coronavirus (SARS-CoV-2) in the COVID-19 pandemic has highlighted the need for effective treatments, as rapid viral mutations complicate therapeutic de....
ascpt.onlinelibrary.wiley.com
March 28, 2025 at 1:00 PM
fetchfeeds.bsky.social
Sumitomo Pharma & NIBIOHN collaborate on universal flu vaccine Phase 1 trials. 🌍💉 #協力研究 #インフルエンザ総合投与 #Phase1Trial https://fefd.link/E6Vfn
February 3, 2025 at 6:46 AM
bionewscentral.com
##StemCell derived ##ChimericAntigenReceptor (CAR) ##NaturalKillerCells show potential for treating ##BCellLymphomas and could make future cellular ##immunotherapies less expensive and more accessible to patients.
##Phase1Trial
New cellular immunotherapy approach shows promise for B-cell lymphoma – BioNews Central
Stem-cell-derived chimeric antigen receptor (CAR) natural killer cells show potential for treating B-cell lymphomas and could make future cellular immunotherapies less expensive and more accessible to patients. ...
sbee.link
January 15, 2025 at 1:02 PM
gmj-georgia.bsky.social
BREAKTHROUGH: First human trial of Lassa fever vaccine shows promising results! The dual rabies-Lassa vaccine proved safe and triggered immune responses agains…

#HemorrhagicFever #Lassafever #Phase1trial #Vaccinedevelopment #WestAfrica

#HemorrhagicFever #Lassafever #Phase1trial #Vaccinedevelopm…
First Lassa Fever Vaccine Shows Promise in Trial
BREAKTHROUGH: First human trial of Lassa fever vaccine shows promising results! The dual rabies-Lassa vaccine proved safe and triggered immune responses agains… #HemorrhagicFever #Lassafever #Phase1trial #Vaccinedevelopment #WestAfrica
news.gmj.ge
June 24, 2026 at 10:43 AM
gmj-georgia.bsky.social
🧬 BREAKTHROUGH: Novel bispecific T cell engager IMA401 targeting MAGE-A4/MAGE-A8 shows encouraging safety & efficacy signals in phase 1a trial…

#Bispecificantibodies #Cancerimmunotherapy #MAGEA4 #Phase1trial #Tcellengager

#Bispecificantibodies #Cancerimmunotherapy #MAGEA4 #Phase1trial #Tcelleng…
New Cancer Therapy Shows Promise in Phase 1 Trial
🧬 BREAKTHROUGH: Novel bispecific T cell engager IMA401 targeting MAGE-A4/MAGE-A8 shows encouraging safety & efficacy signals in phase 1a trial… #Bispecificantibodies #Cancerimmunotherapy #MAGEA4 #Phase1trial #Tcellengager
news.gmj.ge
June 8, 2026 at 12:18 PM